HCPs Favor Tech Over Meds for Type 2 Diabetes

The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) in Amsterdam, Netherlands, has just concluded, and the revelations from Dexcom's report are shaking up the diabetes care landscape. The report, based on a survey of over 2,500 individuals across Europe and the Middle East, shows a clear preference among healthcare professionals (HCPs) for continuous glucose monitoring (CGM) technology over traditional medication for managing Type 2 diabetes. This shift could have profound implications for the future of diabetes care and the companies leading the charge in this space.



The report's findings are nothing short of groundbreaking. A staggering 52% of HCPs favor CGM technology and education over medication for Type 2 diabetes management. This preference is backed by data showing that 93% of CGM users reported a positive impact, significantly exceeding pre-use expectations of 77%. Moreover, 96% of HCPs agreed that CGM should be standard care for multiple daily insulin injection users. These numbers are a wake-up call for the pharmaceutical industry, which has long dominated the diabetes care market.

But what does this mean for Dexcom, the company behind the G7 15 Day system? For starters, it positions Dexcom as a leader in the diabetes technology space. The G7 15 Day system's industry-leading 8.0% MARD (mean absolute relative difference) is a key technical metric where lower numbers indicate superior accuracy in continuous glucose monitoring. This positions Dexcom as having potentially the most accurate CGM sensor on the market, a critical competitive differentiator in the diabetes technology space.



The strategic advantages of Dexcom's new integrations with the Omnipod 5 Automated Insulin Delivery System and NovoPen smart insulin pens cannot be overstated. These integrations create a hybrid closed-loop system that automates insulin adjustments, enhancing patient outcomes by reducing the burden of manual insulin management. This automation can improve patient adherence by making the process more convenient and less error-prone, thereby increasing the likelihood that patients will consistently use the system.

Furthermore, the integration with NovoPen smart insulin pens addresses the larger market of non-pump users, allowing Dexcom to reach a broader audience. This expansion to non-pump users can capture a larger segment of the diabetes market, potentially increasing Dexcom's market share. The unique Follow app connectivity during Omnipod use represents a technical differentiation that competitors currently can't match, providing real-time monitoring and support that can enhance patient adherence.

The 8.0% MARD achievement for Dexcom's G7 15 Day system significantly enhances its competitive edge in the diabetes technology market. The extended 15-day wear period offers both patient convenience and economic advantages, with fewer sensor changes translating to reduced per-patient costs. This could make CGM technology more affordable and accessible to a larger patient population, potentially leading to increased reimbursement and insurance coverage.

The multi-region survey provides Dexcom with evidence-based ammunition for policymakers to expand CGM reimbursement beyond traditional Type 1 patients. With HCPs increasingly viewing CGM as standard care, Dexcom is positioning for substantial market expansion if reimbursement barriers can be overcome. This strategic focus on both product superiority and expanded market access through targeted research demonstrates a sophisticated approach to driving future growth.

In conclusion, the preference of HCPs for CGM technology over medication for Type 2 diabetes management is a game-changer. Dexcom's G7 15 Day system, with its superior accuracy and strategic integrations, is well-positioned to capitalize on this shift. The company's focus on the Type 2 diabetes market, which represents 90-95% of the 134 million people with diabetes across Europe, Middle East, and North Africa, further strengthens its market positioning. As the diabetes care landscape continues to evolve, Dexcom's innovative approach to diabetes management is poised to lead the way.